These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28364582)

  • 21. Lack of Associations between TLR9 and MYD88 Gene Polymorphisms and Risk of Chronic Lymphocytic Leukemia.
    Ali YB; Foad RM; Abdel-Wahed E
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3245-3250. PubMed ID: 29286214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing.
    Minervini CF; Cumbo C; Orsini P; Brunetti C; Anelli L; Zagaria A; Minervini A; Casieri P; Coccaro N; Tota G; Impera L; Giordano A; Specchia G; Albano F
    Diagn Pathol; 2016 Oct; 11(1):96. PubMed ID: 27724982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia.
    Lahiri O; Harris S; Packham G; Howell M
    Cancer Genet Cytogenet; 2007 Nov; 179(1):36-44. PubMed ID: 17981213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
    Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
    Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome.
    Weich N; Ferri C; Moiraghi B; Bengió R; Giere I; Pavlovsky C; Larripa I; Fundia A
    Blood Cells Mol Dis; 2016 Jul; 59():129-33. PubMed ID: 27282582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
    Malcikova J; Pavlova S; Kozubik KS; Pospisilova S
    Hum Mutat; 2014 Jun; 35(6):663-71. PubMed ID: 24415659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia.
    Kochethu G; Delgado J; Pepper C; Starczynski J; Hooper L; Krishnan S; Fegan C; Pratt G
    Leuk Res; 2006 Sep; 30(9):1113-8. PubMed ID: 16458962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germ-line genetic variation of TP53 in osteosarcoma.
    Savage SA; Burdett L; Troisi R; Douglass C; Hoover RN; Chanock SJ;
    Pediatr Blood Cancer; 2007 Jul; 49(1):28-33. PubMed ID: 17096406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients.
    Rombout A; Stamatopoulos B; Lagneaux L; Lust S; Offner F; Naessens E; Vanderstraeten H; Verhasselt B; Philippé J
    PLoS One; 2015; 10(3):e0121526. PubMed ID: 25811490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia.
    Karabon L; Partyka A; Jasek M; Lech-Maranda E; Grzybowska-Izydorczyk O; Bojarska-Junak A; Pawlak-Adamska E; Tomkiewicz A; Robak T; Rolinski J; Frydecka I
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):137-145. PubMed ID: 27933341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.
    Garces S; Khoury JD; Kanagal-Shamanna R; Salem A; Wang SA; Ok CY; Hu S; Patel KP; Routbort MJ; Luthra R; Tang G; Schlette EJ; Bueso-Ramos CE; Medeiros LJ; Loghavi S
    Hum Pathol; 2018 Dec; 82():215-231. PubMed ID: 30086334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
    Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
    Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
    Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
    Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
    J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
    Chang H; Jiang AM; Qi CX
    Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
    Dufour A; Palermo G; Zellmeier E; Mellert G; Duchateau-Nguyen G; Schneider S; Benthaus T; Kakadia PM; Spiekermann K; Hiddemann W; Braess J; Truong S; Patten N; Wu L; Lohmann S; Dornan D; GuhaThakurta D; Yeh RF; Salogub G; Solal-Celigny P; Dmoszynska A; Robak T; Montillo M; Catalano J; Geisler CH; Weisser M; Bohlander SK
    Blood; 2013 May; 121(18):3650-7. PubMed ID: 23525797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.
    Pekova S; Mazal O; Cmejla R; Hardekopf DW; Plachy R; Zejskova L; Haugvicova R; Jancuskova T; Karas M; Koza V; Smolej L; Bezdickova L; Kozak T
    Leuk Res; 2011 Jul; 35(7):889-98. PubMed ID: 21232794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients.
    Willander K; Dutta RK; Ungerbäck J; Gunnarsson R; Juliusson G; Fredrikson M; Linderholm M; Söderkvist P
    BMC Cancer; 2013 Jun; 13():274. PubMed ID: 23734977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
    Pozzo F; Dal Bo M; Peragine N; Bomben R; Zucchetto A; Rossi F; Degan M; Rossi D; Chiarenza A; Grossi A; Di Raimondo F; Zaja F; Pozzato G; Secchiero P; Gaidano G; Del Poeta G; Zauli G; Fo À R; Guarini A; Gattei V
    J Hematol Oncol; 2013 Nov; 6():83. PubMed ID: 24283248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.